MA55490A - Mutéine de lipocaline pour le traitement de l'asthme - Google Patents

Mutéine de lipocaline pour le traitement de l'asthme

Info

Publication number
MA55490A
MA55490A MA055490A MA55490A MA55490A MA 55490 A MA55490 A MA 55490A MA 055490 A MA055490 A MA 055490A MA 55490 A MA55490 A MA 55490A MA 55490 A MA55490 A MA 55490A
Authority
MA
Morocco
Prior art keywords
asthma
treatment
lipocalin mutein
lipocalin
mutein
Prior art date
Application number
MA055490A
Other languages
English (en)
Inventor
Lena Therese Axelsson
Ingmar Bruns
David Robert Close
Mary Fitzgerald
Philip Gardiner
Aulikki Ingergard Alexandra Jauhianinen
Gabriele Matschiner
Gunnel Marita Olsson
Ekaterina Pardali
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA55490A publication Critical patent/MA55490A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Otolaryngology (AREA)
  • Cell Biology (AREA)
MA055490A 2019-03-29 2020-03-25 Mutéine de lipocaline pour le traitement de l'asthme MA55490A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826791P 2019-03-29 2019-03-29
US201962845774P 2019-05-09 2019-05-09
US201962906443P 2019-09-26 2019-09-26

Publications (1)

Publication Number Publication Date
MA55490A true MA55490A (fr) 2022-02-09

Family

ID=70008540

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055490A MA55490A (fr) 2019-03-29 2020-03-25 Mutéine de lipocaline pour le traitement de l'asthme

Country Status (11)

Country Link
US (1) US20220193191A1 (fr)
EP (1) EP3946415A1 (fr)
JP (1) JP2022526524A (fr)
KR (1) KR20210146934A (fr)
CN (1) CN113613669A (fr)
AU (1) AU2020252050A1 (fr)
CA (1) CA3133422A1 (fr)
IL (1) IL286756A (fr)
MA (1) MA55490A (fr)
SG (1) SG11202109839YA (fr)
WO (1) WO2020200960A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210146999A (ko) * 2019-03-29 2021-12-06 피어이스 파마슈티컬즈 게엠베하 리포칼린 뮤테인의 흡입 투여
MX2023007174A (es) 2020-12-18 2023-09-08 Astrazeneca Ab Formulacion de polvo seco de muteina de lipocalina para el tratamiento del asma.
EP4470569A1 (fr) 2022-01-29 2024-12-04 Shanghai Shengdi Pharmaceutical Co., Ltd Conjugué de médicament de glucocorticoïde
CN114780621B (zh) * 2022-06-23 2022-10-04 中铁电气化勘测设计研究院有限公司 一种轨道交通接触网缺陷检索方法
CN121568722A (zh) 2023-07-28 2026-02-24 江苏恒瑞医药股份有限公司 一种含有糖皮质激素的抗体药物偶联物的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
EP1430136A1 (fr) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteines d'apolipoproteine d
WO2003029462A1 (fr) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteines de la lipocaline neutrophile humaine associee a la gelatinase et de proteines apparentees
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP2899277A1 (fr) 2004-11-26 2015-07-29 Pieris AG Composé à affinité pour l'antigène associé aux lymphocytes T cytotoxiques (CTLA-4)
CN104650213A (zh) 2006-08-01 2015-05-27 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
US8986951B2 (en) 2010-06-08 2015-03-24 Pieris Ag Tear lipocalin in muteins binding IL-4 R alpha
ES2863410T3 (es) * 2011-12-13 2021-10-11 Pieris Pharmaceuticals Gmbh Métodos para prevenir o tratar ciertos trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores.

Also Published As

Publication number Publication date
US20220193191A1 (en) 2022-06-23
IL286756A (en) 2021-10-31
KR20210146934A (ko) 2021-12-06
CN113613669A (zh) 2021-11-05
JP2022526524A (ja) 2022-05-25
SG11202109839YA (en) 2021-10-28
AU2020252050A1 (en) 2021-11-11
WO2020200960A1 (fr) 2020-10-08
EP3946415A1 (fr) 2022-02-09
CA3133422A1 (fr) 2020-10-08

Similar Documents

Publication Publication Date Title
MA55490A (fr) Mutéine de lipocaline pour le traitement de l'asthme
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
EP3866781A4 (fr) Nouvelles compositions pour le traitement de maladies inflammatoires
EP3765611A4 (fr) Oligonucléotides ciblant la pcsk9 pour le traitement de l'hypercholestérolémie et d'états apparentés
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
EP3642667C0 (fr) Lentille de contact d'orthokératologie pour le traitement de la myopie
EP3612215A4 (fr) Compositions et procédés pour le traitement d'inflammation pulmonaire
EP3890747A4 (fr) Compositions pour le traitement de la fibrose et de l'inflammation
EP3946357A4 (fr) Formulations topiques pour le traitement de neuropathies périphériques
MA55218A (fr) Eskétamine pour le traitement de la dépression
MA52961A (fr) Compositions et procédés pour la réduction ou le traitement d'une inflammation
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3861131A4 (fr) Thérapie génique pour le traitement de l'acidémie propionique
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3810091A4 (fr) Méthodes et compositions pour le traitement de l'hypertension pulmonaire
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP3612214A4 (fr) Optimisation d'enzymothérapie de remplacement pour le traitement de l'homocystinurie
EP4192453A4 (fr) Utilisation de dexpramipexole pour le traitement de l'asthme modéré à sévère
EP3952881A4 (fr) Compositions et procédés pour le traitement d'inconfort des lentilles de contact
FR24C1053I2 (fr) Utilisation du delgocitinib pour le traitement de l'eczéma des mains chronique
EP3400942A4 (fr) Utilisation de dérivés de quinoléine pour le traitement du cancer de l' sophage et procédé de traitement, composition pharmaceutique et trousse associée
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
MA55982A (fr) Composition pharmaceutique pour le traitement de tumeurs